ACOX3

Across TCGA pan-cancer cohorts, ACOX3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ACOX3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ACOX3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ACOX3 is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where ACOX3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACOX3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.768	<.001	11	view →
CCRCC	Male	All	−0.633	<.001	7	view →
LSCC	Male	II,III,IV	−0.521	<.001	7	view →
LUAD	Male	III,IV	−0.417	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ACOX3–HNSC

Open the HNSC breakdown →